Antimicrobial Drug–Resistant Shiga Toxin–Producing Escherichia coli Infections, Michigan, USA

Sanjana Mukherjee, Rebekah E. Mosci, Chase M. Anderson, Brian A. Snyder, James Collins, James T. Rudrik, Shannon D. Manning

Author affiliations: Michigan State University, East Lansing, Michigan, USA (S. Mukherjee, R.E. Mosci, C.M. Anderson, B.A. Snyder, S.D. Manning); Michigan Department of Health and Human Services, Lansing, Michigan (J. Collins, J.T. Rudrik)

DOI: https://doi.org/10.3201/eid2309.170523

High frequencies of antimicrobial drug resistance were observed in O157 and non-O157 Shiga toxin–producing E. coli strains recovered from patients in Michigan during 2010–2014. Resistance was more common in non-O157 strains and independently associated with hospitalization, indicating that resistance could contribute to more severe disease outcomes.

S

higa toxin–producing Escherichia coli (STEC) contributes to 265,000 cases of foodborne illness annually in the United States (/). Most infections are caused by O157 strains; however, non-O157 STEC infections have increased (2). Antimicrobial drug resistance among STEC has been reported (3–5) but is probably underestimated. Given the importance of resistance in E. coli pathotypes, we sought to determine the prevalence of resistant STEC infections and assess the effects of resistance on disease.

We obtained 358 STEC isolates from the Michigan Department of Health and Human Services (MDHHS) Reference Laboratory (Lansing, MI, USA), collected during 2010–2014. Of these, 14 were outbreak associated. We examined 1 strain per outbreak using protocols approved by Michigan State University (MSU; Lansing, MI, USA; IRB #10-736SM) and MDHHS (842-PHALAB). Overall, 31 (8.8%) strains (23 non-O157, 8 O157) were resistant to antimicrobial drugs (Table). Resistance to ampicillin (7.4%) was most common, followed by trimethoprim/sulfamethoxazole (SXT) (4.0%) and ciprofloxacin (0.3%). Compared with national rates, resistance to ampicillin and SXT was higher, but not significantly different, for O157 isolates from Michigan (online Technical Appendix Figure 1, https://wwwnc.cdc.gov/EID/article/23/9/17-0523-Techapp1.pdf) (6). One strain was resistant to all drugs, and all resistant strains had high MICs (ampicillin, >64 μg/mL; ciprofloxacin, >32 μg/mL; SXT, in 1:19 ratio, >32/608 μg/mL). Notably, resistance was twice as common for non-O157 (11.1%) than for O157 (5.5%) strains. O111 strains (n = 7) had significantly higher resistance frequencies (24.1%) than other non-O157 serogroups (p = 0.03). We found variation by year and season; resistance frequencies were highest in 2012 (online Technical Appendix, Figure 2) and during winter/spring (online Technical Appendix Table 1), but neither trend was significant. We also observed a strong but nonsignificant association between resistance and hospitalization but no association for urban versus rural residence (7) or county after stratifying by prescription rates (8) in the univariate analyses.

We conducted a multivariate analysis using logistic regression, with hospitalization as the dependent variable; we included variables with significant (p≤0.05) and strong (p≤0.20) associations from the univariate analysis as independent variables. Forward selection indicated that hospitalized patients were more likely to have resistant infections (odds ratio [OR] 2.4, 95% CI 1.00–5.82) and less likely to have non-O157 infections (OR 0.4, 95% CI 0.21–0.61) (online Technical Appendix Table 2), suggesting that resistant infections or O157 infections may cause more severe clinical outcomes. Patients ≥18 years of age, women, and patients with bloody diarrhea were also more likely to be hospitalized.

Although we found no significant difference by stx profile, strains possessing stx1 only were more commonly resistant than strains with stx2 alone (p = 0.27 by Fisher exact test). All 23 (100%) resistant non-O157 STEC and 1
(12.5%) resistant O157 strain had stx1 only. Strains positive for eae were less likely to be resistant (n = 27; 8.4%) than eae-negative strains (n = 4; 23.5%); this nonsignificant difference (p = 0.07 by Fisher exact test) could be due to small sample sizes. All 8 resistant O157 strains and 18 (78.3%) of 23 resistant non-O157 strains had eae, demonstrating correlations between virulence genes and serogroups.

Overall, we detected a high frequency of resistance among non-O157 STEC (11.2%), similar to findings from Mexico (15%), although we evaluated fewer drugs (5). Resistance to ciprofloxacin was low despite its routine use for treating enteric infections, perhaps because development in E. coli requires multiple mutations (9). Resistance frequencies in STEC were low relative to other E. coli pathotypes such as extraintestinal E. coli, which may be attributable to differences in the source of the infections (3).

The higher O157 resistance frequencies in Michigan than nationwide indicate that selection pressures vary by location and source. Although we observed no difference in resistance frequencies for counties with high versus low antimicrobial drug prescription rates (8), we have not investigated selection pressures from drug use in farm environments that may affect resistance emergence in Michigan. Approximately 12 × 10⁶ kg of antimicrobial drugs are administered to food animals annually in the United States; roughly 61% of these are medically relevant. Higher resistance frequencies in winter/spring (12.2%) than summer/fall (7.5%) could be attributed to variation in prescription rates by season (10).

Because Michigan is not part of the Centers for Disease Control and Prevention Foodborne Diseases Active Surveillance Network and resistance in STEC has not been widely researched, data about the prevalence and impact of resistance are lacking. This study detected a high frequency of STEC resistance to antimicrobial drugs commonly used in human and veterinary medicine, particularly for non-O157 serotypes, which have increased in frequency (2). Monitoring resistance in STEC is essential because of the risk of transmitting resistant strains from food animals to humans and the high likelihood of horizontal transfer of resistance genes from STEC to other pathogens. Routine monitoring can uncover new treatment approaches and guide development of strategies for controlling emergence and spread of resistance in STEC and other E. coli pathotypes.

Acknowledgments

We thank Ben Hutton and Jason Wholehan for help with specimen processing and isolation.

This work was supported by the National Institutes of Health Enterics Research Investigational Network Cooperative Research Center (U19AI090872 to S.D.M.) and the US Department of Agriculture National Institute of Food and Agriculture (2011-67005-30004 to S.D.M.). The Department of Microbiology and Molecular Genetics at MSU and the Ronald and Sharon Rogowski Fellowship provided student support to S.M.

Miss Mukherjee is a PhD student in the Department of Microbiology and Molecular Genetics at MSU. She is studying antimicrobial drug resistance in STEC and nontyphoidal Salmonella. Her primary research interests are molecular epidemiology and medical microbiology.

References

1. Scallan E,霍克斯特拉 RM, 安格洛 FJ, 塔乌克 RX, Widdowson MA, Roy SL, et al. Foodborne illness acquired in the United States—major pathogens. Emerg Infect Dis. 2011;17:7–15. http://dx.doi.org/10.3201/eid1701.P11101

2. Tseng M, Sha Q, Rudrik JT, Collins J, Henderson T, Funk JA, et al. Increasing incidence of non-O157 Shiga toxin-producing Escherichia coli (STEC) in Michigan and association with clinical illness. Epidemiol Infect. 2016;144:1394–405. http://dx.doi.org/10.1017/S0950268815002836

3. Schroeder CM, Meng J, Zhao S, DeRoy C, Torcolini J, Zhao C, et al. Antimicrobial resistance of Escherichia coli O26, O103, O111, O128, and O145 from animals and humans. Emerg Infect Dis. 2002;8:1409–14. http://dx.doi.org/10.3201/eid0812.0200770

4. Mora A, Blanco JE, Blanco M, Alonso MP, Dahi G, Eccheta A, et al. Antimicrobial resistance of Shiga toxin (verotoxin)–producing Escherichia coli O157:H7 and non-O157 strains isolated from humans, cattle, sheep and food in Spain. Res Microbiol. 2005;156:793–806. http://dx.doi.org/10.1016/j.resmic.2005.03.006

5. Amézquita-López BA, Quiñones B, Soto-Beltrán M, Lee BG, Yambo JC, Lugo-Melchor OY, et al. Antimicrobial resistance profiles of Shiga toxin-producing Escherichia coli O157 and...
non-O157 recovered from domestic farm animals in rural communities in northwestern Mexico. Antimicrob Resist Infect Control. 2016;5(1–6). http://dx.doi.org/10.1186/s13756-015-0100-5
6. Centers for Disease Control and Prevention. NARMS now: human data 2016 [cited 2016 Oct 12]. http://www.cdc.gov/narms/now/
7. Ingram DD, Franco SJ. 2013 NCHS urban-rural classification scheme for counties. Vital Health Stat 2. 2014;166(1):1–73.
8. Center for Healthcare Research and Transformation. Antibiotic prescribing and use. 2011 [cited 2016 Oct 12]. http://www.chrt.org/document/antibiotic-prescribing-and-use/
9. Jacoby GA. Mechanisms of resistance to quinolones. Clin Infect Dis. 2005;41(Suppl 2):S120–6. http://dx.doi.org/10.1086/428052
10. Suda KJ, Hicks LA, Roberts RM, Hunkler RJ, Taylor TH. Trends and seasonal variation in outpatient antibiotic prescription rates in the United States, 2006 to 2010. Antimicrob Agents Chemother. 2014;58:2763–6. http://dx.doi.org/10.1128/AAC.02239-13

Address for correspondence: Shannon D. Manning, 1129 Farm Ln, Michigan State University, East Lansing, MI 48824, USA; email: mannin71@msu.edu

White-Nose Syndrome Fungus in a 1918 Bat Specimen from France

Michael G. Campana, Naoko P. Kurata, Jeffrey T. Foster, Lauren E. Helgen, DeeAnn M. Reeder, Robert C. Fleischer, Kristofer M. Helgen

Author affiliations: Smithsonian Institution, Washington, DC, USA (M.G. Campana, N.P. Kurata, L.E. Helgen, R.C. Fleischer); University of New Hampshire, Durham, New Hampshire, USA (J.T. Foster); Bucknell University, Lewisburg, Pennsylvania, USA (D.M. Reeder); University of Adelaide, Adelaide, South Australia, Australia (K.M. Helgen)

DOI: https://doi.org/10.3201/eid2309.170875

White-nose syndrome, first diagnosed in North America in 2006, causes mass deaths among bats in North America. We found the causative fungus, *Pseudogymnoascus destructans*, in a 1918 sample collected in Europe, where bats have now adapted to the fungus. These results are consistent with a Eurasian origin of the pathogen.

We report the earliest known historical incidence of the fungus *Pseudogymnoascus* (formerly *Gemoecys*) *destructans*, detected in a museum specimen of a bat (*Myotis bechsteinii*) collected in France in 1918. This fungal pathogen causes white-nose syndrome (WNS) in bats. Since its introduction into eastern North America around 2006, WNS has devastated bat populations across the continent (2). *P. destructans* has also been found across the Eurasian landmass (3,4) without documented mass bat deaths. Epidemiologic evidence among bats and fungal genetics indicate that the fungus has been recently introduced into North American bat populations (5–7).

To clarify the epidemiologic history of WNS and to investigate physical evidence of its presence in specific locations in the past, we screened 138 19th- and 20th-century bat specimens (housed at the National Museum of Natural History [USNM], Washington, DC) from North America (n = 41), Europe (n = 83), and East Asia (n = 14) for *P. destructans* DNA (online Technical Appendix, https://wwwnc.cdc.gov/EID/article/23/9/17-0875-Techapp1.pdf). We sampled dry museum skins and intact bodies stored in 70% ethanol; some were originally fixed in formalin. We swabbed bat rostra and wings to collect potentially preserved *P. destructans* biomolecules and stored swabs in 100% ethanol until DNA extraction.

We extracted DNA in a dedicated ancient DNA laboratory at the National Zoological Park (Washington, DC) by using stringent protocols to prevent false positive results from modern DNA contamination (8). Before extraction, we removed swabs from the ethanol and let them air dry. We then let swabs digest overnight at 55°C in 600 μL extraction buffer (1 × Tris-EDTA buffer, pH 8.0, 0.019 mmol/L EDTA, 0.01 mmol/L NaCl, 1% SDS, 10 mg/mL DTT, and 1 mg/mL protease K) (8). Later extractions omitted DTT. We extracted digested samples twice in 600 μL phenol and once in 600 μL chloroform. We removed and concentrated the aqueous phase by using Amicon Ultra-4 30 kDa molecular weight cutoff columns (Millipore Sigma, Merck, Billerica, MA, USA) to a final volume of ≥250 μL. We included 1 extraction blank for every 10–11 historical samples.

We screened extracts for *P. destructans* by using a previously described species-specific quantitative PCR targeting 103 bp (including primers) of the intergenic spacer region (9). Each extract was amplified in 2–8 replicate PCRs. Multiple, no-template controls (2,3) were included in each PCR setup. Positive products from experiments in which quantifiable contamination (>0.1 genome equivalents/μL sample) was observed in ≥1 negative control were discarded; these experiments were repeated with fresh reagents.

One sample (USNM 231170) tested positive in 2 of 3 PCRs. We performed a second independent extraction on this sample. The replicate extraction tested positive in 4 of 5 PCRs. Two of the USNM 231170–positive PCR products were confirmed by using Sanger sequencing and comparison to publicly available *P. destructans* sequences in GenBank. These sequences were 100% identical to *P. destructans* sequences from North America (GenBank accession nos. JX270192.1
Antimicrobial Drug–Resistant Shiga Toxin–Producing *Escherichia coli* Infections, Michigan, USA

Technical Appendix

**Technical Appendix Table 1.** Univariate analysis highlighting factors associated with antibiotic resistance in 358 clinical *Shiga toxin–producing Escherichia coli* (STEC) in Michigan, 2010–2014

| Characteristic | Total strains* | No (%) resistant | OR (95% CI†) | p-value‡ |
|---------------|----------------|-----------------|--------------|----------|
| **Pathogen factors** | | | | |
| **Serotype** | | | | |
| O157 | 146 | 8 (5.5) | 1.0 | — |
| Non-O157 | 207 | 23 (11.1) | 2.2 (0.94–4.97) | 0.066 |
| **stx profile** | | | | |
| stx1 | 205 | 25 (12.2) | 1.9 (0.72–5.28) | 0.18 |
| stx2 | 75 | 5 (6.7) | 1.0 | — |
| stx1, stx2 | 77 | 2 (2.6) | 0.3 (0.07–1.99) | 0.27 |
| **eae presence** | | | | |
| Yes | 323 | 27 (8.4) | 0.3 (0.10–1.04) | 0.05 |
| No | 18 | 4 (22.2) | 1.0 | — |
| **Outbreak associated** | | | | |
| Yes | 14 | 1 (7.1) | 0.8 (0.10–6.14) | 0.81 |
| No | 344 | 31 (9.0) | 1.0 | — |
| **Demographics and other factors** | | | | |
| **Residence** | | | | |
| Urban | 153 | 13 (8.5) | 0.9 (0.43–1.90) | 0.80 |
| Rural | 205 | 19 (9.3) | 1.0 | — |
| **Age, y** | | | | |
| 0–18 | 154 | 12 (7.8) | 1.0 | — |
| 19–64 | 172 | 17 (9.9) | 1.3 (0.60–2.81) | 0.51 |
| >65 | 32 | 3 (9.4) | 1.2 (0.32–4.61) | 0.76 |
| **Sex** | | | | |
| Male | 173 | 14 (8.1) | 1.0 | — |
| Female | 185 | 18 (9.7) | 1.2 (0.59–2.54) | 0.59 |
| **Antimicrobial-drug prescription rates by county** | | | | |
| High | 109 | 13 (11.9) | 1.6 (0.78–3.45) | 0.19 |
| Low | 249 | 19 (7.6) | 1.0 | — |
| **Season** | | | | |
| Winter and spring | 115 | 14 (12.2) | 1.7 (0.83–3.62) | 0.14 |
| Summer and fall | 243 | 18 (7.4) | 1.0 | — |
| **Clinical factors** | | | | |
| **Abdominal pain** | | | | |
| Yes | 279 | 27 (9.7) | 1.4 (0.48–4.23) | 0.53 |
| No | 57 | 4 (7.0) | 1.0 | — |
| **Body ache** | | | | |
| Yes | 55 | 7 (12.7) | 1.6 (0.64–3.83) | 0.33 |
| No | 281 | 24 (8.5) | 1.0 | — |
| **Bloody diarrhea** | | | | |
| Yes | 232 | 21 (9.1) | 0.9 (0.42–2.06) | 0.87 |
| No | 104 | 10 (9.6) | 1.0 | — |
| **Hemolytic uremic syndrome (HUS)** | | | | |
| Yes | 6 | 0 (0) | — | 1.0 |
| No | 331 | 31 (9.4) | — | — |
| **Hospitalization** | | | | |
| Yes | 106 | 13 (12.3) | 1.7 (0.80–3.61) | 0.16 |
| No | 237 | 18 (7.6) | 1.0 | — |

*Epidemiological data and case information were retrieved from the Michigan Disease Surveillance System (MDSS). SAS 9.3 (SAS Institute, Cary, NC) and Epi Info™ 7 (CDC) were used for statistical analyses. Depending on the variable examined, the number of isolates do not add up to the total (n=358) because of missing data.
| Characteristic                              | Total strains* | No (%) resistant | OR (95% CI†) | p-value‡ |
|--------------------------------------------|----------------|------------------|--------------|----------|
| Serotype O157                              | 138            | 63 (45.7%)       | 1.0          | –        |
| Non-O157                                   | 200            | 42 (21.0%)       | 0.3 (0.20–0.51) | <0.0001  |
| stx profile                                |                |                  |              |          |
| stx1                                       | 198            | 43 (21.7%)       | 1.0          | 0.13     |
| stx2                                       | 72             | 33 (45.8%)       | 1.7 (0.86–3.20) |          |
| stx1,stx2                                  | 72             | 30 (41.7%)       | 1.0          |          |
| eae presence                               |                |                  |              |          |
| Yes                                        | 310            | 92 (29.7)        | 0.5 (0.20–1.50) | 0.23     |
| No                                         | 16             | 7 (43.8)         | 1.0          | –        |
| Outbreak associated                        |                |                  |              |          |
| Yes                                        | 14             | 7 (50.0)         | 2.5 (0.79–6.80) | 0.11     |
| No                                         | 329            | 99 (30.1)        | 1.0          | –        |
| Antimicrobial drug resistant isolate        |                |                  |              |          |
| Yes                                        | 31             | 13 (41.9)        | 1.7 (0.80–3.61) | 0.16     |
| No                                         | 312            | 93 (29.8)        | 1.0          | –        |
| Sex                                        |                |                  |              |          |
| Male                                       | 166            | 39 (23.5)        | 1.0          | –        |
| Female                                     | 177            | 67 (37.9)        | 2.0 (1.24–3.17) | 0.004    |
| Age, y                                     |                |                  |              |          |
| 0–18                                       | 145            | 35 (24.1)        | 1.0          | –        |
| 19–64                                      | 167            | 56 (33.5)        | 1.6 (0.96–2.61) | 0.07     |
| >65                                        | 31             | 15 (48.4)        | 2.9 (1.32–6.56) | 0.007    |
| Abdominal pain                             |                |                  |              |          |
| Yes                                        | 277            | 95 (34.3)        | 2.2 (1.08–4.41) | 0.03     |
| No                                         | 57             | 11 (19.3)        | 1.0          | –        |
| Body ache                                  |                |                  |              |          |
| Yes                                        | 55             | 20 (36.4)        | 1.3 (0.70–2.35) | 0.42     |
| No                                         | 279            | 86 (30.8)        | 1.0          | –        |
| Bloody diarrhea                            |                |                  |              |          |
| Yes                                        | 230            | 91 (39.6)        | 3.9 (2.12–7.13) | <0.0001  |
| No                                         | 104            | 15 (14.4)        | 1.0          | –        |
| Hemolytic uremic syndrome (HUS)            |                |                  |              |          |
| Yes                                        | 5              | 4 (80.0)         | 9.0 (0.99–81.45) | 0.02     |
| No                                         | 328            | 101 (30.8)       | 1.0          | –        |

**Technical Appendix Table 2. Univariate and multivariate analyses to identify factors associated with hospitalization**

| Characteristic                              | OR  | 95% CI‡ | p-value† |
|--------------------------------------------|-----|---------|----------|
| Sex: F                                     | 1.9 | 1.15–3.32 | 0.02     |
| Age, y: 18                                 | 1.9 | 1.15–3.28 | 0.014    |
| Serogroup: non-O157                        | 0.4 | 0.21–0.61 | 0.0002   |
| Antimicrobial drug resistant isolate: Yes   | 2.4 | 1.00–5.82 | 0.05     |
| Bloody diarrhea: Yes                       | 3.9 | 1.99–7.65 | <0.0001  |

* Depending on the variable examined, the number of isolates do not add up to the total (n=358) because of missing data. All 6 HUS cases had O157 strains with eae, though 3 had stx1,stx2 and the other 3 had stx2 infections.
†95% confidence interval (CI) for odds ratio (OR)
‡p-value was calculated by Chi-square test; Fisher exact test was used for variables ≤5 in at least 1 cell.
§Logistic regression was performed using forward selection while controlling for variables that yielded significant (P≤0.05) and strong (P≤0.20) associations with hospitalization in the univariate analysis. The model was adjusted for age, sex, serogroup, stx profile, outbreak status, resistance, HUS, and bloody diarrhea. Only those variables yielding significant associations are presented; Hosmer and Lemeshow Goodness-of-Fit test (P= 0.73). All variables were tested for collinearity.
¶Wald 95% confidence intervals (CI)
Technical Appendix Figure 1. Frequency of any resistance to ampicillin, ciprofloxacin and trimethoprim-sulfamethoxazole among O157 and non-O157 Shiga toxin producing *E. coli* (STEC) isolates recovered from patients in Michigan, 2010–2014
Technical Appendix Figure 2. Frequency of resistance to various antimicrobials among STEC O157 isolates in Michigan compared to those reported by the National Antimicrobial Resistance Monitoring System (NARMS), 2010-2014. Abbreviation: AMP, ampicillin; CIP, ciprofloxacin; SXT, trimethoprim-sulfamethoxazole